Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;204(5):1590-1592.
doi: 10.1111/bjh.19439. Epub 2024 Apr 2.

Sequence not salvage

Douglas W Sborov  1 , Gliceida Galarza Fortuna  1 , Patrick J Hayden  2
Affiliations

Sequence not salvage

Douglas W Sborov et al. Br J Haematol. 2024 May.

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of multiple myeloma (MM) has fundamentally changed the relapsed and refractory therapeutic landscape, but the disease remains incurable. Two CAR-T products, idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti), have been FDA- and EMA-approved for the treatment of relapsed/refractory MM (RRMM); both target B-cell maturation antigen (BCMA), a surface glycoprotein highly expressed on MM cells. Despite deep and durable responses following CAR-T therapy, most patients will need subsequent treatment, and the optimal next-line therapy is presently unclear. Commentary on: Liu et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2. Br J Haematol 2024;204:1780-1789.

Keywords: T‐cell redirecting bispecific antibodies; chimeric antigen receptor (CAR) T‐cell therapy; multiple myeloma; proteosome inhibitor.

PubMed Disclaimer

References

REFERENCES

    1. Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti‐B‐cell maturation antigen chimeric antigen receptor T‐cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE‐1 2‐year follow‐up. J Clin Oncol. 2023;41(6):1265–1274. https://doi.org/10.1200/jco.22.00842
    1. Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four‐year follow‐up of LCAR‐B38M in relapsed or refractory multiple myeloma: a phase 1, single‐arm, open‐label, multicenter study in China (LEGEND‐2). J Hematol Oncol. 2022;15(1):86. https://doi.org/10.1186/s13045‐022‐01301‐8
    1. Liu R, Yang R, Xu X, Zhao W, Wang F, Zhang W, et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA‐specific CAR‐T therapy: a retrospective analysis of LEGEND‐2. Br J Haematol. 2024;204:1780–1789.
    1. Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, et al. Salvage therapies including retreatment with BCMA‐directed approaches following BCMA CAR‐T relapses for multiple myeloma. Blood Adv. 2024. https://doi.org/10.1182/bloodadvances.2023012066
    1. van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA‐directed CAR T therapy. Blood. 2023;141(7):756–765.

MeSH terms

Substances